486 related articles for article (PubMed ID: 15843454)
21. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis.
Setoguchi S; Solomon DH; Weinblatt ME; Katz JN; Avorn J; Glynn RJ; Cook EF; Carney G; Schneeweiss S
Arthritis Rheum; 2006 Sep; 54(9):2757-64. PubMed ID: 16947774
[TBL] [Abstract][Full Text] [Related]
22. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden.
Raaschou P; Simard JF; Holmqvist M; Askling J;
BMJ; 2013 Apr; 346():f1939. PubMed ID: 23568792
[TBL] [Abstract][Full Text] [Related]
23. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study.
Lee SJ; Chang H; Yazici Y; Greenberg JD; Kremer JM; Kavanaugh A
J Rheumatol; 2009 Aug; 36(8):1611-7. PubMed ID: 19369454
[TBL] [Abstract][Full Text] [Related]
24. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.
Baecklund E; Iliadou A; Askling J; Ekbom A; Backlin C; Granath F; Catrina AI; Rosenquist R; Feltelius N; Sundström C; Klareskog L
Arthritis Rheum; 2006 Mar; 54(3):692-701. PubMed ID: 16508929
[TBL] [Abstract][Full Text] [Related]
25. Cancer in patients with rheumatic diseases exposed to TNF antagonists.
Carmona L; Abasolo L; Descalzo MA; Pérez-Zafrilla B; Sellas A; de Abajo F; Gomez-Reino JJ; ;
Semin Arthritis Rheum; 2011 Aug; 41(1):71-80. PubMed ID: 21093020
[TBL] [Abstract][Full Text] [Related]
26. Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis.
Al-Aly Z; Pan H; Zeringue A; Xian H; McDonald JR; El-Achkar TM; Eisen S
Transl Res; 2011 Jan; 157(1):10-8. PubMed ID: 21146146
[TBL] [Abstract][Full Text] [Related]
27. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.
Jacobsson LT; Turesson C; Gülfe A; Kapetanovic MC; Petersson IF; Saxne T; Geborek P
J Rheumatol; 2005 Jul; 32(7):1213-8. PubMed ID: 15996054
[TBL] [Abstract][Full Text] [Related]
28. Trends in medication and health-related quality of life in a population-based rheumatoid arthritis register in Malmo, Sweden.
Söderlin MK; Lindroth Y; Jacobsson LT
Rheumatology (Oxford); 2007 Aug; 46(8):1355-8. PubMed ID: 17567634
[TBL] [Abstract][Full Text] [Related]
29. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
30. Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma.
Baecklund E; Sundström C; Ekbom A; Catrina AI; Biberfeld P; Feltelius N; Klareskog L
Arthritis Rheum; 2003 Jun; 48(6):1543-50. PubMed ID: 12794821
[TBL] [Abstract][Full Text] [Related]
31. B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor alpha antagonists: differential effects between good and poor clinical responders.
La DT; Collins CE; Yang HT; Migone TS; Stohl W
Ann Rheum Dis; 2008 Aug; 67(8):1132-8. PubMed ID: 17967830
[TBL] [Abstract][Full Text] [Related]
32. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.
Leombruno JP; Einarson TR; Keystone EC
Ann Rheum Dis; 2009 Jul; 68(7):1136-45. PubMed ID: 18753157
[TBL] [Abstract][Full Text] [Related]
33. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate.
Buchbinder R; Barber M; Heuzenroeder L; Wluka AE; Giles G; Hall S; Harkness A; Lewis D; Littlejohn G; Miller MH; Ryan PF; Jolley D
Arthritis Rheum; 2008 Jun; 59(6):794-9. PubMed ID: 18512713
[TBL] [Abstract][Full Text] [Related]
34. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis.
Bernatsky S; Clarke AE; Suissa S
Arch Intern Med; 2008 Feb; 168(4):378-81. PubMed ID: 18299492
[TBL] [Abstract][Full Text] [Related]
35. [Malignancy risk during TNF-blocking therapy increased or not?].
Nurmohamed MT
Ned Tijdschr Geneeskd; 2012; 156(21):A4812. PubMed ID: 22617075
[TBL] [Abstract][Full Text] [Related]
36. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis.
Wu E; Chen L; Birnbaum H; Yang E; Cifaldi M
Curr Med Res Opin; 2008 Aug; 24(8):2229-40. PubMed ID: 18577308
[TBL] [Abstract][Full Text] [Related]
37. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
[TBL] [Abstract][Full Text] [Related]
38. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
[TBL] [Abstract][Full Text] [Related]
39. Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis.
Askling J; Klareskog L; Hjalgrim H; Baecklund E; Björkholm M; Ekbom A
Ann Rheum Dis; 2005 Dec; 64(12):1765-8. PubMed ID: 15843445
[TBL] [Abstract][Full Text] [Related]
40. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study.
den Broeder AA; Creemers MC; Fransen J; de Jong E; de Rooij DJ; Wymenga A; de Waal-Malefijt M; van den Hoogen FH
J Rheumatol; 2007 Apr; 34(4):689-95. PubMed ID: 17117492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
